Regulation of bone metabolism by nuclear receptors

Molecular and Cellular Endocrinology

Volumn 310, Issue 1-2, 2009, Pages 3-10

  Imai, Yuuki ^a,b   Kondoh, Shino ^b   Kouzmenko, Alexander ^b,c   Kato, Shigeaki ^b,c  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Bone; Cre loxP; Nuclear receptor; Osteoclast; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANDROGEN RECEPTOR; CALCIUM; CATHEPSIN K; CD11B ANTIGEN; COLONY STIMULATING FACTOR 1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FAS LIGAND; FIBROBLAST GROWTH FACTOR 23; FOLLITROPIN; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR; I KAPPA B KINASE; INTERLEUKIN 1; INTERLEUKIN 7; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D RECEPTOR;

APOPTOSIS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CALCIUM METABOLISM; DRUG POTENCY; DRUG TARGETING; ESTROGEN DEFICIENCY; HUMAN; METABOLIC REGULATION; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; BONE AND BONES; ESTROGENS; HUMANS; ORGAN SPECIFICITY; OSTEOCLASTS; OSTEOPOROSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 67649096645     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.08.015     Document Type: Review

References (94)

1. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., Terauchi Y., Harada Y., Azuma Y., Nakamura K., Kadowaki T., and Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113 (2004) 846-855
2. Aubin J.E. Osteoprogenitor cell frequency in rat bone marrow stromal populations: role for heterotypic cell-cell interactions in osteoblast differentiation. J. Cell Biochem. 72 (1999) 396-410
3. Bonewald L.F., and Johnson M.L. Osteocytes, mechanosensing and Wnt signaling. Bone 42 (2008) 606-615
4. Canalis E. Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81 (1996) 3441-3447
5. Chiu W.S., McManus J.F., Notini A.J., Cassady A.I., Zajac J.D., and Davey R.A. Transgenic mice that express Cre recombinase in osteoclasts. Genesis 39 (2004) 178-185
6. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., and Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8 (1999) 265-277
7. Cole T.J., Blendy J.A., Monaghan A.P., Krieglstein K., Schmid W., Aguzzi A., Fantuzzi G., Hummler E., Unsicker K., and Schutz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 9 (1995) 1608-1621
8. Devleta B., Adem B., and Senada S. Hypergonadotropic amenorrhea and bone density: new approach to an old problem. J. Bone Miner. Metab. 22 (2004) 360-364
9. Draper M.W. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann. N.Y. Acad. Sci. 997 (2003) 373-377
10. Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P., and Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127 (2000) 4277-4291
11. Ebeling P.R. Clinical practice. Osteoporosis in men. N. Engl. J. Med. 358 (2008) 1474-1482
12. Emmelot-Vonk M.H., Verhaar H.J., Nakhai Pour H.R., Aleman A., Lock T.M., Bosch J.L., Grobbee D.E., and van der Schouw Y.T. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 299 (2008) 39-52
13. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., Yu X., Rauch F., Davis S.I., Zhang S., Rios H., Drezner M.K., Quarles L.D., Bonewald L.F., and White K.E. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38 (2006) 1310-1315
14. Ferron M., and Vacher J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. Genesis 41 (2005) 138-145
15. Fitzpatrick L.A. Estrogen therapy for postmenopausal osteoporosis. Arq. Bras. Endocrinol. Metabol. 50 (2006) 705-719
16. Forrest D., Golarai G., Connor J., and Curran T. Genetic analysis of thyroid hormone receptors in development and disease. Recent Prog. Horm. Res. 51 (1996) 1-22
17. Fraichard A., Chassande O., Plateroti M., Roux J.P., Trouillas J., Dehay C., Legrand C., Gauthier K., Kedinger M., Malaval L., Rousset B., and Samarut J. The T3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production. EMBO J. 16 (1997) 4412-4420
18. Gothe S., Wang Z., Ng L., Kindblom J.M., Barros A.C., Ohlsson C., Vennstrom B., and Forrest D. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev. 13 (1999) 1329-1341
19. Gowen M., Lazner F., Dodds R., Kapadia R., Feild J., Tavaria M., Bertoncello I., Drake F., Zavarselk S., Tellis I., Hertzog P., Debouck C., and Kola I. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14 (1999) 1654-1663
20. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., and Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1192
21. Harman S.M. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend. Med. 3 (2006) 254-269
22. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., Dominguez C.E., and Jurutka P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13 (1998) 325-349
23. Henderson N.K., and Sambrook P.N. Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Curr. Opin. Rheumatol. 8 (1996) 365-369
24. Holick M.F. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest. 116 (2006) 2062-2072
25. Hukkanen M., Platts L.A., Lawes T., Girgis S.I., Konttinen Y.T., Goodship A.E., MacIntyre I., and Polak J.M. Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Bone 32 (2003) 142-149
26. Ishida Y., and Heersche J.N. Glucocorticoid-induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J. Bone Miner. Res. 13 (1998) 1822-1826
27. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab. 4 (2006) 341-348
28. Kawano H., Sato T., Yamada T., Matsumoto T., Sekine K., Watanabe T., Nakamura T., Fukuda T., Yoshimura K., Yoshizawa T., Aihara K., Yamamoto Y., Nakamichi Y., Metzger D., Chambon P., Nakamura K., Kawaguchi H., and Kato S. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 9416-9421
29. Kim H.J., Zhao H., Kitaura H., Bhattacharyya S., Brewer J.A., Muglia L.J., Ross F.P., and Teitelbaum S.L. Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Invest. 116 (2006) 2152-2160
30. Krum S.A., Miranda-Carboni G.A., Hauschka P.V., Carroll J.S., Lane T.F., Freedman L.P., and Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 27 (2008) 535-545
31. Kumar T.R. What have we learned about gonadotropin function from gonadotropin subunit and receptor knockout mice?. Reproduction 130 (2005) 293-302
32. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., Dacquin R., Mee P.J., McKee M.D., Jung D.Y., Zhang Z., Kim J.K., Mauvais-Jarvis F., Ducy P., and Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell 130 (2007) 456-469
33. Li M., Indra A.K., Warot X., Brocard J., Messaddeq N., Kato S., Metzger D., and Chambon P. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 407 (2000) 633-636
34. Li C.Y., Jepsen K.J., Majeska R.J., Zhang J., Ni R., Gelb B.D., and Schaffler M.B. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J. Bone Miner. Res. 21 (2006) 865-875
35. Lohnes D., Mark M., Mendelsohn C., Dolle P., Dierich A., Gorry P., Gansmuller A., and Chambon P. Function of the retinoic acid receptors (RARs) during development (I). Craniofacial and skeletal abnormalities in RAR double mutants. Development 120 (1994) 2723-2748
36. Lorenz-Depiereux B., Bastepe M., Benet-Pages A., Amyere M., Wagenstaller J., Muller-Barth U., Badenhoop K., Kaiser S.M., Rittmaster R.S., Shlossberg A.H., Olivares J.L., Loris C., Ramos F.J., Glorieux F., Vikkula M., Juppner H., and Strom T.M. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 38 (2006) 1248-1250
37. Lukert B.P. Osteoporosis: prevention and treatment. Compr. Ther. 16 (1990) 36-42
38. Lukert B.P., and Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 112 (1990) 352-364
39. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., and Evans R.M. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
40. Masuyama R., Nakaya Y., Tanaka S., Tsurukami H., Nakamura T., Watanabe S., Yoshizawa T., Kato S., and Suzuki K. Dietary phosphorus restriction reverses the impaired bone mineralization in vitamin D receptor knockout mice. Endocrinology 142 (2001) 494-497
41. Masuyama R., Stockmans I., Torrekens S., Van Looveren R., Maes C., Carmeliet P., Bouillon R., and Carmeliet G. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 116 (2006) 3150-3159
42. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
43. Meyer T., Kneissel M., Mariani J., and Fournier B. In vitro and in vivo evidence for orphan nuclear receptor RORalpha function in bone metabolism. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9197-9202
44. Miller P.D., Chines A.A., Christiansen C., Hoeck H.C., Kendler D.L., Lewiecki E.M., Woodson G., Levine A.B., Constantine G., and Delmas P.D. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J. Bone Miner. Res. 23 (2008) 525-535
45. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., Harada Y., Azuma Y., Krust A., Yamamoto Y., Nishina H., Takeda S., Takayanagi H., Metzger D., Kanno J., Takaoka K., Martin T.J., Chambon P., and Kato S. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130 (2007) 811-823
46. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 288 (2002) 872-881
47. Notini A.J., McManus J.F., Moore A., Bouxsein M., Jimenez M., Chiu W.S., Glatt V., Kream B.E., Handelsman D.J., Morris H.A., Zajac J.D., and Davey R.A. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J. Bone Miner. Res. 22 (2007) 347-356
48. Ohtake F., Baba A., Takada I., Okada M., Iwasaki K., Miki H., Takahashi S., Kouzmenko A., Nohara K., Chiba T., Fujii-Kuriyama Y., and Kato S. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446 (2007) 562-566
49. Osella G., Terzolo M., Reimondo G., Piovesan A., Pia A., Termine A., Paccotti P., and Angeli A. Serum markers of bone and collagen turnover in patients with Cushing's syndrome and in subjects with adrenal incidentalomas. J. Clin. Endocrinol. Metab. 82 (1997) 3303-3307
50. Pacifici R. Estrogen deficiency, T cells and bone loss. Cell Immunol. (2007)
51. Pearce G., Tabensky D.A., Delmas P.D., Baker H.W., and Seeman E. Corticosteroid-induced bone loss in men. J. Clin. Endocrinol. Metab. 83 (1998) 801-806
52. Pereira R.M., Delany A.M., and Canalis E. Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28 (2001) 484-490
53. Pereira R.C., Delany A.M., and Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 30 (2002) 685-691
54. Purpura K.A., Aubin J.E., and Zandstra P.W. Sustained in vitro expansion of bone progenitors is cell density dependent. Stem Cells 22 (2004) 39-50
55. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115 (2005) 3318-3325
56. Rajendren G., Zhou H., Moonga B.S., Zaidi M., and Sun L. Restoration of bone mass in hpg mouse by preoptic area grafting. Ann. N.Y. Acad. Sci. 1068 (2006) 341-347
57. Reim N.S., Breig B., Stahr K., Eberle J., Hoeflich A., Wolf E., and Erben R.G. Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J. Bone Miner. Res. 23 (2008) 694-704
58. Roggia C., Gao Y., Cenci S., Weitzmann M.N., Toraldo G., Isaia G., and Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 13960-13965
59. Roggia C., Tamone C., Cenci S., Pacifici R., and Isaia G.C. Role of TNF-alpha producing T-cells in bone loss induced by estrogen deficiency. Minerva Med. 95 (2004) 125-132
60. Rosen C.J. Clinical practice. Postmenopausal osteoporosis. N. Engl. J. Med. 353 (2005) 595-603
61. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., Kagan R., Chen E., Petruschke R.A., Thompson D.E., and de Papp A.E. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20 (2005) 141-151
62. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20 (2006) 1405-1428
63. Russell R.G. Bisphosphonates: from bench to bedside. Ann. N.Y. Acad. Sci. 1068 (2006) 367-401
64. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., Kavanagh K.L., Triffitt J.T., Lundy M.W., Phipps R.J., Barnett B.L., Coxon F.P., Rogers M.J., Watts N.B., and Ebetino F.H. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N.Y. Acad. Sci. 1117 (2007) 209-257
65. Ryan M.R., Shepherd R., Leavey J.K., Gao Y., Grassi F., Schnell F.J., Qian W.P., Kersh G.J., Weitzmann M.N., and Pacifici R. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 16735-16740
66. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., Moritz J.D., Schu P., and von Figura K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13453-13458
67. Sakai K., and Miyazaki J. A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. Biochem. Biophys. Res. Commun. 237 (1997) 318-324
68. Seibel M.J., Dunstan C.R., Zhou H., Allan C.M., and Handelsman D.J. Sex steroids, not FSH, influence bone mass. Cell 127 (2006) 1079 author reply 1080-1
69. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet. 8 (2007) 829-833
70. Sims N.A., Dupont S., Krust A., Clement-Lacroix P., Minet D., Resche-Rigon M., Gaillard-Kelly M., and Baron R. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30 (2002) 18-25
71. Sims N.A., Clement-Lacroix P., Minet D., Fraslon-Vanhulle C., Gaillard-Kelly M., Resche-Rigon M., and Baron R. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J. Clin. Invest. 111 (2003) 1319-1327
72. Sims N.A., Brennan K., Spaliviero J., Handelsman D.J., and Seibel M.J. Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E456-E462
73. Sowers M.R., Jannausch M., McConnell D., Little R., Greendale G.A., Finkelstein J.S., Neer R.M., Johnston J., and Ettinger B. Hormone predictors of bone mineral density changes during the menopausal transition. J. Clin. Endocrinol. Metab. 91 (2006) 1261-1267
74. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P., and Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276 (2001) 8836-8840
75. Sun L., Peng Y., Sharrow A.C., Iqbal J., Zhang Z., Papachristou D.J., Zaidi S., Zhu L.L., Yaroslavskiy B.B., Zhou H., Zallone A., Sairam M.R., Kumar T.R., Bo W., Braun J., Cardoso-Landa L., Schaffler M.B., Moonga B.S., Blair H.C., and Zaidi M. FSH directly regulates bone mass. Cell 125 (2006) 247-260
76. Syed F., and Khosla S. Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328 (2005) 688-696
77. Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M., Youn M.Y., Takeyama K., Nakamura T., Mezaki Y., Takezawa S., Yogiashi Y., Kitagawa H., Yamada G., Takada S., Minami Y., Shibuya H., Matsumoto K., and Kato S. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat. Cell Biol. 9 (2007) 1273-1285
78. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T., and Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76 (1994) 969-976
79. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7 (2007) 292-304
80. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., Ito M., Takeshita S., and Ikeda K. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5 (2007) 464-475
81. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4 (2003) 638-649
82. Vanderschueren D., Vandenput L., Boonen S., Lindberg M.K., Bouillon R., and Ohlsson C. Androgens and bone. Endocr. Rev. 25 (2004) 389-425
83. Wan Y., Chong L.W., and Evans R.M. PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 13 (2007) 1496-1503
84. Weaver C.M. Vitamin D, calcium homeostasis, and skeleton accretion in children. J. Bone Miner. Res. 22 Suppl. 2 (2007) V45-V49
85. Weinstein R.S. Glucocorticoid-induced osteoporosis. Rev. Endocr. Metab. Disord. 2 (2001) 65-73
86. Weinstein R.S., and Manolagas S.C. Apoptosis and osteoporosis. Am. J. Med. 108 (2000) 153-164
87. Weitzmann M.N., and Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116 (2006) 1186-1194
88. Weitzmann M.N., and Pacifici R. Estrogen regulation of immune cell bone interactions. Ann. N.Y. Acad. Sci. 1068 (2006) 256-274
89. Weitzmann M.N., Roggia C., Toraldo G., Weitzmann L., and Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 110 (2002) 1643-1650
90. Windahl S.H., Andersson G., and Gustafsson J.A. Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrinol. Metab. 13 (2002) 195-200
91. Wu J., Wang X.X., Takasaki M., Ohta A., Higuchi M., and Ishimi Y. Cooperative effects of exercise training and genistein administration on bone mass in ovariectomized mice. J. Bone Miner. Res. 16 (2001) 1829-1836
92. Yagishita N., Yamamoto Y., Yoshizawa T., Sekine K., Uematsu Y., Murayama H., Nagai Y., Krezel W., Chambon P., Matsumoto T., and Kato S. Aberrant growth plate development in VDR/RXR gamma double null mutant mice. Endocrinology 142 (2001) 5332-5341
93. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., Kawakami T., Arioka K., Sato H., Uchiyama Y., Masushige S., Fukamizu A., Matsumoto T., and Kato S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16 (1997) 391-396
94. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 13 (2007) 791-801